Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will release its financial results for the quarter ending March 31, 2023, post-market on May 8, 2023. A conference call to discuss the results is scheduled for 4:30 PM ET on the same day. Interested participants can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. The event will also be available via live and archived webcast on the Establishment Labs investor relations webpage.
Establishment Labs specializes in medical technology focused on women's health, offering products like the Motiva® breast devices, which are backed by over 200 patents. The company operates two manufacturing facilities in Costa Rica, adhering to strict regulatory standards.